p21 - Negative regulator of the cell cycle

Proceedings of the Society for Experimental Biology and Medicine

Volumn 213, Issue 2, 1996, Pages 138-149

  Gartel, Andrei L ^a   Serfas, Michael S ^a   Tyner, Angela L ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; PROTEIN P21; PROTEIN P53;

CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; DNA DAMAGE; GENE EXPRESSION; GENE INDUCTION; GENE THERAPY; HUMAN; MITOSIS INHIBITION; NONHUMAN; REGULATORY MECHANISM; REVIEW;

EID: 0029906786     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-213-44046     Document Type: Review

References (126)

1. Morgan DO. Principles of CDK regulation. Nature 374:131-134, 1995.
2. Kato J, Matsuoka M, Strom D, Sherr C. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol 14:2713-2721, 1994.
3. Sherr C, Roberts J. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995.
4. Bates S, Bonetta L, Macallan D, Parry D, Holder A, Dickson C, Peters G. CDK6 and CDK4 are distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9:71-79, 1994.
5. Dulic V, Lees E, Reed S. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257:1958-1961, 1992.
6. Reznitzky D, Reed S. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol 15:3463-3469, 1995.
7. Hinds PW, Weinberg RA. Tumor suppressor genes. Curr Opin Genet Dev 4:135-141, 1994.
8. Lam E, Thangue N. DP and E2F proteins: Coordinating transcription with cell cycle progression. Curr Opin Cell Biol 6:859-866, 1994.
9. Picksley SM, Lane DP. p53 and Rb: Their cellular roles. Curr Opin Cell Biol 6:853-858, 1994.
10. Muller R. Transcriptional regulation during the mammalian cell cycle. TIG 11:173-178, 1995.
11. Cardoso MC, Leonhardt H, Nadal-Ginard B. Reversal of terminal differentiation and control of DNA replication: Cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell 74:979-992, 1993.
12. Fang F, Newport JW. Distinct roles of cdk2 and cdc2 in RP-A phosphorylation during the cell cycle. J Cell Sci 106:983-994, 1993.
13. Adachi Y, Laemmli UK. Study of the cell cycle-dependent assembly of the DNA pre-replication centers in Xenopus egg extracts. EMBO J 13:4153-4164, 1994.
14. Yan H, Newport J. An analysis of the regulation of DNA synthesis by cdk2, Cip1, and licensing factor. J Cell Biol 129:1-15, 1995.
15. CIP1. J Cell Biol 130:755-769, 1995.
16. Harper JW, Adami G, Wei N, Keyomarsi K, Elledge S. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993.
17. Xiong Y, Hannon G, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
18. El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J, Lin D, Mercer W, Kinzler K, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
19. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98, 1994.
20. Jiang H, Lin J, Su Z, Collart F, Huberman E, Fisher P. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9:3397-3406, 1994.
21. Polyak K, Lee M, Erdjument-Bromage H, Koff A, Roberts J, Tempst P, Massague J. Cloning of p27, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994.
22. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin/ cdk protein kinase activity, is related to p21. Cell 78:67-74, 1994.
23. Lee M, Reynisdottir I, Massague J. Cloning of p57, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649, 1995.
24. Matsuoka S, Edwards M, Bai C, Parker S, Zhang P, Baldini A, Harper J, Elledge S. p57, a structurally distinct member of the p21 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662, 1995.
25. Kamb A, Gruis N, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian S, Stockert E, Day R III, Johnson B, Skolnick M. A cell cycle regulator involved in genesis of many tumor types. Science 264:436-440, 1994.
26. Serrano M, Hannon G, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/cdk4. Nature 366:704-707, 1993.
27. ink4b is a potential effector of cell cycle arrest mediated by TGF-β. Nature 371:257-261, 1994.
28. Hirai H, Roussel MF, Kato JY, Ashmun RA, Scherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672-2681, 1995.
29. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 15:2682-2688, 1995.
30. Huppi K, Siwarski D, Dosik J, Michieli P, Chedid M, Reed S, Mock B, Givol D, Mushinski JF. Molecular cloning, sequencing, chromosomal location and expression of mouse p21 (Waf1). Oncogene 9:3017-3020, 1994.
31. Zhu L, Harlow E, Dynlacht BD. p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev 9:1740-1752, 1995.
32. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4:897-906, 1993.
33. Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin dependent kinases is associated with cellular transformation. Genes Dev 7:1572-1583, 1993.
34. Skp2 are essential elements of the Cyclin A-CDK2 S phase kinase. Cell 82:915-925, 1995.
35. Zhang H, Hannon G, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8:1750-1758, 1994.
36. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai L, Zhang P, Dobtowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N. Inhibition of cyclin dependent kinases by p21. Mol Biol Cell 6:387-400, 1995.
37. Aprelikova O, Xiong Y, Liu ET. Both p16 and p21 families of cyclin dependent kinase inhibitors block the phosphorylation of cyclin dependent kinases by the CDK-activating kinase. J Biol Chem 270:18195-18197, 1995.
38. Waga S, Hannon G, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578, 1994.
39. Li R, Waga S, Hannon G, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA dependent DNA replication and repair. Nature 371:534-537, 1994.
40. Flores-Rozas H, Kelman Z, Dean FB, Pan ZQ, Harper JW, Elledge SJ, O'Donnell MO, Hurwitz J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci U S A 91:8655-8659, 1994.
41. Shivji KK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69:367-374, 1992.
42. Shivji MK, Grey SJ, Strausfeld UP, Wood RD, Blow JJ. Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision-repair. Curr Biol 4:1062-1068, 1994.
43. Pan ZQ, Reardon JT, Li L, Flores-Rozas H, Legerski R, Sancar A, Hurwitz J. Inhibition of nucleotide excision repair by the cyclin E-dependent kinase inhibitor p21. J Biol Chem 270:22008-22016, 1995.
44. Podust VN, Podust LM, Goubin F, Ducommun B, Hubscher U. Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the cyclin-dependent kinase inhibitor p21. Biochemistry 34:8869-8875, 1995.
45. WAF-1 gene activities. Mol Cell Biol 16:1786-1793, 1996.
46. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386-388, 1995.
47. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21. Nature 375:159-161, 1995.
48. Warbrick E, Lane DP, Glover DM, Cox LS. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclic-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol 5:275-282, 1995.
49. Nakanishi M, Robetorye RS, Pereira-Smith OM, Smith JR. The C-terminal region of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J Biol Chem 270:17060-17063, 1995.
50. Zakut R, Givol D. The tumor suppression function of p21 Waf is contained in its N-terminal half ('half-WAF'). Oncogene 11:393-395, 1995.
51. Goubin F, Ducommun B. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor. Oncogene 10:2281-2287, 1995.
52. Hall M, Bates S, Peteres G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11:1581-1588, 1995.
53. Nakanishi M, Robetorye RS, Adami R, Pereira-Smith OM, Smith JR. Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1. EMBO J 14:555-563, 1995.
54. Cip1. Oncogene 11:1675-1681, 1995.
55. Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9:600-611, 1995.
56. Waf1/Cip1 with PCNA. Oncogene 11:1931-1937, 1995.
57. Gartel AL, Serfas MS, Gartel M, Goufman E, Wu GS, El-Deiry WS, Tyner AL. p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp Cell Res 227:171-181, 1996.
58. Parker S, Eichele G, Zhang P, Rawls A, Sands A, Bradley A, Olson E, Harper J, Elledge S. p53-independent expression of p21 in muscle and other terminally differentiating cells. Science 267:1024-1027, 1995.
59. Halevy O, Novitch B, Spicer D, Skapek S, Rhee J, Hannon G, Beach D, Lassar A. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1021, 1995.
60. Missero C, Calautti E, Eckner R, Chin J, Tsai L, Livingston D, Dotto GP. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci U S A 92:5451-5455, 1995.
61. Steinman R, Hoffman B, Iro A, Guillouf C, Liebermann D, El-Houseini M. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 9:3389-3396, 1994.
62. Michieli P, Chedid D, Lin D, Pierce J, Mercer W, Givol D. Inhibition of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391-3395, 1994.
63. Jiang H, Lin J, Su Z, Herlyn M, Kerbel R, Weissman B, Welch D, Fisher P. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 10:1855-1864, 1995.
64. Schmid P, Lorenz A, Hameister H, Montenarh M. Expression of p53 during mouse embryogenesis. Development 113:857-865, 1991.
65. Macleod K, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935-944, 1995.
66. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculscu VE, Burrel M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B. Topological control of p21 (WAF1/ CIP1) expression in normal and neoplastic tissues. Cancer Res 55:2910-2919, 1995.
67. Brugarolas J, Chadrasekaran C, Gordon J, Beach D, Jacks T, Hannon G. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557, 1995.
68. Deng C, Zhang P, Harper J, Elledge S, Leder P. Mice lacking p21 undergo normal development, but defective in G1 checkpoint control. Cell 82:675-684, 1995.
69. de Nooij JC, Hariharan IK. Uncoupling cell fate determination from patterned cell division in the Drosophila eye. Science 270:983-985, 1995.
70. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993.
71. Lowe SW, Schmidt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993.
72. Dulic V, Kaufman WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994.
73. Namba H, Hara T, Tukazaki T, Migita K, Ishikawa N, Ito K, Nagataki S, Yamashita S. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res 55:2075-2080, 1995.
74. Akashi M, Hachiya M, Osawa W, Spinn K, Suzuki G, Koeffler H. Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. J Biol Chem 270:19181-19187, 1995.
75. Hirano Y, Yamato K, Tsuchida N. A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down. Oncogene 1085:1879-1885, 1995.
76. Clarke AR, Gledhill S, Hoper ML, Bird CC, Wyllie AH. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 9:1767-1773, 1994.
77. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, Hall PA. The role of p53 in spontaneous and radiation induced apoptosis in the gastrointestinal tract of normal and p53 deficient mice. Cancer Res 5420:614-617, 1994.
78. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994.
79. Katayose D, Wersto R, Cowan K, Seth P. Consequences of p53 gene expression by adenovirus vector on cell cycle arrest and apoptosis in human aortic vascular smooth muscle cells. Biochem Biophys Res Commun 215:446-451, 1995.
80. Lin Y, Benchimol S. Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest. Mol Cell Biol 15:6045-6054, 1995.
81. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370:220-223, 1994.
82. WAF1/CIP1 in breast epithelial cells. Cancer Res 55:4520-4524, 1995.
83. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez G, Clarke MF. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci U S A 91:5878-5882, 1994.
84. Wagner AJ, Kokontis JM, Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev 8:2817-2830, 1994.
85. Hermeking H, Funk JO, Reichert M, Ellwart JW, Eick D. Abrogation of p53-induced cell cycle arrest by c-Myc: Evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene 11:1409-1415, 1995.
86. Lin D, Fiscella M, O'Connor PM, Jackman J, Chen M, Luo LL, Sala A, Travail S, Appella E, Mercer WE. Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc Natl Acad Sci U S A 91:10079-10083, 1994.
87. Tahara H, Sato E, Noda A, Ide T. Increase in expression level of p21sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene 10:835-840, 1995.
88. Bond JA, Blaydes JP, Rowson J, Haughton MF, Smith JR, Wynford-Thomas D, Wyllie FS. Mutant p53 reduces human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res 55:2404-2409, 1995.
89. Bae I, Fan S, Bhatia K, Kohn KW, Fornace AJ, O'Connor PM. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells. Cancer Res 5585:2387-2393, 1995.
90. Gudas J, Nguyen H, Li T, Hill D, Cowan K. Effects of cell cycle, wild-type p53 and DNA damage on p21 CIP1/WAF1 expression in human breast epithelial cells. Oncogene 11:253-261, 1995.
91. Scheffner M, Huibregste JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505, 1993.
92. Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by Cyclin D1-dependent kinase. Science 267:1022-1024, 1995.
93. Pinto M, Robine-Leon S, Appay MD, Kedinger M, Triadou N, Dussaulx E, Lacroix B, Simmon-Assmann P, Haffen K, Fogh J, Zweibaum A. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line CaCo-2 in culture. Biol Cell 47:323-330, 1983.
94. Fan Z, Lu Y, Wu X, DeBlasio A, Koff A, Mendelsohn J. Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand induced A431 cell growth inhibition. J Cell Biol 131:235-242, 1995.
95. Chin YE, Kitagawa M, Su W-CS, You Z-H, Iwamoto Y, Fu X-Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272:719-722, 1996.
96. Ihle JN, Kerr IM. Jaks and STATS in signaling by the cytokine receptor superfamily. Trends Genet 11:69-74, 1995.
97. Decker SJ. Nerve growth factor induced growth arrest and induction of p21 Cip1/WAF1 in NIH-3T3 Cells expressing TrkA. J Biol Chem 270:30841-30844, 1995.
98. Zhang W, Grasso L, McClain C, Gambel A, Cha Y, Travail S, Deisseroth A, Mercer W. p53-independent induction of WAF1/ CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55:668-674, 1995.
99. Jeoung DI, Tang B, Sonenberg M. Induction of tumor suppressor p21 protein by kinase inhibitors in MCF-7 cells. Biochem Biophys Res Commun 214:361-366, 1995.
100. Johnson M, Dimitrov D, Vojta P, Barrett J, Noda A, Pereira-Smith O, Smith J. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog 11:59-64, 1994.
101. Shao ZM, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, Ordonez JV, Shroot B, Fontana JA. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11:493-504, 1995.
102. Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, Fiscella M, Jackman J, O'Connor P, Anderson C, Appella E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 270:29386-29391, 1995.
103. Derynck R. TGF-β-receptor-mediated signaling. TIBS 19:548-553, 1994.
104. Reynisdottir I, Polyak K, Iavorne A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9:1831-1845, 1995.
105. Datto M, Li Y, Panus J, Howe D, Xiong Y, Wang X. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 92:5545-5549, 1995.
106. Elbendary E. Transforming growth factor β can induce CIP1/ WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5:1301-1307, 1994.
107. Datto MB, Yu Y, Wang X-F. Functional analysis of the transforming growth factor β responsive elements in the WAF1/ CIP1/p21 promoter. J Biol Chem 270:28623-28628, 1995.
108. Biggs JR, Kudlow JE, Kraft AS. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem 271:901-906, 1996.
109. Timchenko NA, Wilde M, Nakanishi M, Smith JR, Darlington GJ. CCAAT/enhancer-binding protein α (C/EBPα) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev 10:804-815, 1996.
110. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153, 1996.
111. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP. Absence of WAFI mutations in a variety of human malignancies. Blood 8484:3781-3784, 1994.
112. Chedid M, Michieli P, Lengel C, Huppi K, Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 9:3021-3024, 1994.
113. Li YJ, Laurent-Puig P, Salmon RJ, Thomas G, Hamelin R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 10:599-601, 1995.
114. Mousses S, Ozcelik H, Lee PD, Malkin D, Bull SB, Andrulis IL. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 4:1089-1092, 1995.
115. Law JC, Deka A. Identification of a Pstl polymorphism in the p21Cip1/Waf1 cyclin-dependent kinase inhibitor gene. Hum Genet 95:459-460, 1995.
116. Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W, Porter AT, Honn KV. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11:1395-1398, 1995.
117. Hollenstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancer. Science 253:49-53, 1991.
118. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221, 1992.
119. Harvey M, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogeninduced tumorigenesis in p53-deficient mice. Nat Genet 5:225-229, 1993.
120. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7, 1994.
121. WAF1/cip1 in human brain tumors. Oncogene 11:2021-2028, 1995.
122. Koopman J, Maintz D, Schild S, Schramm J, Lousi DN, Wiestier OD, von Deimling A. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumors. Br J Cancer 72:1230-1233, 1995.
123. Nakanishi M, Adami G, Robetorye R, Noda A, Venable S, Dimitrov D, Pereira-Smith O, Smith J. Exit from Go and entry into the cell cycle of cells expressing p21 antisense RNA. Proc Natl Acad Sci U S A 92:4352-4356, 1995.
124. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1:1052-1056, 1995.
125. Chen YQ, Cipriano SC, Arenkiel JM, Miller FR. Tumor suppression by p21 (WAF1). Cancer Res 55:4536-4539, 1995.
126. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW, Thompson TC. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155, 1995.